Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial

Young‐Suk Lim(Asan Medical Center), Seungbong Han(Gachon University), Hung‐Da Tung(Center for HIV and Hepatogastroenterology), Jonggi Choi(Ulsan College), Yao‐Chun Hsu(China Medical University), Wonseok Kang(Samsung Medical Center), Ming‐Jong Bair(Mackay Medical College), Neung Hwa Park(Ulsan College), Kuo‐Chih Tseng(Buddhist Tzu Chi General Hospital), Yun Bin Lee(Seoul National University Hospital), Gwang Hyeon Choi(Seoul National University Bundang Hospital), Sheng‐Shun Yang(Taichung Veterans General Hospital), Cheng‐Yuan Peng(China Medical University), Ming‐Lung Yu(National Sun Yat-sen University), Won‐Mook Choi(Ulsan College), Pin‐Nan Cheng(National Cheng Kung University Hospital), Soo Young Park(Kyungpook National University Hospital), Jeong‐Hoon Lee(Ulsan College), Chien‐Hung Chen(Kaohsiung Chang Gung Memorial Hospital), Hyung Joon Kim(Chung-Ang University Hospital), Jihoon T. Kim(Korea University Medical Center), So Young Kwon(Konkuk University Medical Center), Gin‐Ho Lo(E-Da Hospital), Te-Sheng Chang(Chiayi Chang Gung Memorial Hospital), Eun Sun Jang(Seoul National University Bundang Hospital), Chi-Yi Chen(Chia-Yi Christian Hospital), Gi‐Ae Kim(Kyung Hee University)
˜The œLancet. Gastroenterology & hepatology
February 3, 2025
Cited by 23


Related Papers